These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19826477)

  • 21. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics.
    Pekin D; Skhiri Y; Baret JC; Le Corre D; Mazutis L; Salem CB; Millot F; El Harrak A; Hutchison JB; Larson JW; Link DR; Laurent-Puig P; Griffiths AD; Taly V
    Lab Chip; 2011 Jul; 11(13):2156-66. PubMed ID: 21594292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIK3CA mutations and copy number gains in human lung cancers.
    Yamamoto H; Shigematsu H; Nomura M; Lockwood WW; Sato M; Okumura N; Soh J; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Date H; Lam WL; Minna JD; Gazdar AF
    Cancer Res; 2008 Sep; 68(17):6913-21. PubMed ID: 18757405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective targeting of the oncogenic
    Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
    Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
    [No Abstract]   [Full Text] [Related]  

  • 25. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
    Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
    Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethnicity affects
    Soh J; Toyooka S; Matsuo K; Yamamoto H; Wistuba II; Lam S; Fong KM; Gazdar AF; Miyoshi S
    Oncol Lett; 2015 Sep; 10(3):1775-1782. PubMed ID: 26622749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular epidemiology and diagnostics of KRAS mutations in human cancer.
    Timar J; Kashofer K
    Cancer Metastasis Rev; 2020 Dec; 39(4):1029-1038. PubMed ID: 32725342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
    Sartore-Bianchi A; Di Nicolantonio F; Nichelatti M; Molinari F; De Dosso S; Saletti P; Martini M; Cipani T; Marrapese G; Mazzucchelli L; Lamba S; Veronese S; Frattini M; Bardelli A; Siena S
    PLoS One; 2009 Oct; 4(10):e7287. PubMed ID: 19806185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
    Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
    Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.
    Dienstmann R; Elez E; Argiles G; Matos I; Sanz-Garcia E; Ortiz C; Macarulla T; Capdevila J; Alsina M; Sauri T; Verdaguer H; Vilaro M; Ruiz-Pace F; Viaplana C; Garcia A; Landolfi S; Palmer HG; Nuciforo P; Rodon J; Vivancos A; Tabernero J
    Mol Oncol; 2017 Sep; 11(9):1263-1272. PubMed ID: 28618197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
    Fang B
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arsenite malignantly transforms human prostate epithelial cells in vitro by gene amplification of mutated KRAS.
    Merrick BA; Phadke DP; Bostrom MA; Shah RR; Wright GM; Wang X; Gordon O; Pelch KE; Auerbach SS; Paules RS; DeVito MJ; Waalkes MP; Tokar EJ
    PLoS One; 2019; 14(4):e0215504. PubMed ID: 31009485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
    Silva-Oliveira RJ; Silva VA; Martinho O; Cruvinel-Carloni A; Melendez ME; Rosa MN; de Paula FE; de Souza Viana L; Carvalho AL; Reis RM
    Cell Oncol (Dordr); 2016 Jun; 39(3):253-63. PubMed ID: 26920031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
    Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations.
    Myers MB; McKim KL; Wang Y; Banda M; Parsons BL
    Methods Mol Biol; 2020; 2102():395-417. PubMed ID: 31989569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
    Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
    Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.